Reassessment of the actual benefit (AB) and improvement in actual benefit (IAB).
-
Clinical Benefit
Substantial
The actual benefit of VERSATIS is substantial.
Clinical Added Value
minor
The new clinical data available indicates that VERSATIS provides a minor improvement in actual benefit (level IV) in the management of post-herpetic pain in adults.